VIDEO: Expert discusses T-cell lymphoma highlights from ASH
Click Here to Manage Email Alerts
Stefan K. Barta, MD, MS, MRCP, director of the T-Cell Lymphoma Program at Penn Medicine, discussed some promising treatments for T-cell lymphoma presented at the ASH Annual Meeting and Exposition.
Barta summarized a study that determined the addition of oral azacitidine (CC486) to CHOP as initial therapy was feasible and safe in patients with peripheral T-cell lymphoma, and induced a high complete response rate in patients with nodal peripheral T-cell lymphoma with T-follicular helper phenotype. He also highlighted data that showed duvelisib yielded consistent response rates in patients with relapsed/refractory peripheral T-cell lymphoma.
“It’s so important in T-cell lymphoma to look at what patients may benefit,” Barta said.
Collapse
Pro B, et al. Abstract 44. Presented at: ASH Annual Meeting and Exposition (virtual meeting); Dec. 5-8, 2020.
Ruan J, et al. Abstract 40. Presented at: ASH Annual Meeting and Exposition (virtual meeting); Dec. 5-8, 2020.
Read more about
Click Here to Manage Email Alerts